The MPA initiates research on vaccine safety and narcolepsy
The Medical Products Agency (MPA) has previously presented results from studies performed in Sweden on the safety of the pandemic vaccine Pandemrix. To further elucidate an association between narcolepsy and vaccination the MPA has initiated further research. The studies are coordinated by the MPA and are conducted both by in-house and by independent researchers and are expected to be ongoing during 2012. (Source: MPA RSS news -)
Source: MPA RSS news - - February 2, 2012 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Nyheter-2012
(Source: MPA RSS news -)
Source: MPA RSS news - - February 2, 2012 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
The MPA initiates research on vaccine safety and narcolepsy
The Medical Products Agency (MPA) has previously presented results from studies performed in Sweden on the safety of the pandemic vaccine Pandemrix. To further elucidate an association between narcolepsy and vaccination the MPA has initiated further research. The studies are coordinated by the MPA and are conducted both by in-house and by independent researchers and are expected to be ongoing during 2012. (Source: MPA RSS news -)
Source: MPA RSS news - - February 2, 2012 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Nyheter-2012
(Source: MPA RSS news -)
Source: MPA RSS news - - February 2, 2012 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
The MPA initiates research on vaccine safety and narcolepsy
The Medical Products Agency (MPA) has previously presented results from studies performed in Sweden on the safety of the pandemic vaccine Pandemrix. To further elucidate an association between narcolepsy and vaccination the MPA has initiated further research. The studies are coordinated by the MPA and are conducted both by in-house and by independent researchers and are expected to be ongoing during 2012. (Source: MPA RSS news -)
Source: MPA RSS news - - February 2, 2012 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
5,7 million Euro to Swedish research on environmental impact of pharmaceuticals
The MistraPharma research program has been granted 5,7 million Euro (SEK 52 millions) for continued research into the environmental impact of pharmaceuticals by the The Swedish Foundation for Strategic Environmental Research (Mistra).
MistraPharma is supported by the Swedish Medical Products Agency. (Source: MPA RSS news -)
Source: MPA RSS news - - October 5, 2011 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Cooperation agreement finalised with Brazil’s medical products agency ANVISA
The Medical Products Agency has signed a cooperation agreement with its Brazilian counterpart ANVISA. The aim of the agreement is to increase the exchange of information and experience within the areas of the improved use of medical products, sustainable development, resistance to antibiotics, medical technology, electronic submissions and pharmacopoeia and pharmacovigilance activities. (Source: MPA RSS news -)
Source: MPA RSS news - - July 4, 2011 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Swedish initiative for green medicine production
The Swedish Medical Products Agency (MPA) has published a report on how environmental standards in pharmaceutical production can be sharpened within the EU. The proposal is unique and forces all manufacturers to follow the GMP rules on pharmaceuticals sold on the EU markets. In recent years, manufacturing of pharmaceuticals in low cost countries like India and China has drawn attention because of the environmental impact. (Source: MPA RSS news -)
Source: MPA RSS news - - July 4, 2011 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Report from an epidemiological study in Sweden on vaccination with Pandemrix and narcolepsy
The Medical Products Agency in Sweden has conducted a Case Inventory Study which provides strengthened evidence for an association between vaccination with Pandemrix and narcolepsy in children and adolescents, 19 years and younger. (Source: MPA RSS news -)
Source: MPA RSS news - - June 30, 2011 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Changes in procedure for requesting Sweden as RMS in DCP
The Swedish Medical Products Agency participates actively in the decentralised procedure (DCP) as reference member state (RMS) and has since the start received a high number of requests for time slots. (Source: MPA RSS news -)
Source: MPA RSS news - - April 5, 2011 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Strengthened evidence of an association between vaccination with Pandemrix and narcolepsy in children and adolescents
Results from a Swedish registry based cohort study indicate a 4-fold increased risk of narcolepsy in children and adolescents below the age of 20 vaccinated with Pandemrix, compared to children of the same age that were not vaccinated. The results are in line with those of a similar Finish registry study. (Source: MPA RSS news -)
Source: MPA RSS news - - March 29, 2011 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Nyheter 2011
(Source: MPA RSS news -)
Source: MPA RSS news - - January 17, 2011 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Variations - Worksharing for purely nationally authorised products not accepted
Worksharing does not apply to variations for purely nationally authorised products until the variation regulation (EC) 1234/2008 has been updated with information regarding nationally authorised products. (Source: MPA RSS news -)
Source: MPA RSS news - - January 17, 2011 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Pilot project of joint scientific advice - outcome of the evaluation
The outcome of the evaluation of the pilot project of joint scientific advice was very positive. Therefore, the collaboration between the TLV and MPA will continue. (Source: MPA RSS news -)
Source: MPA RSS news - - December 21, 2010 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
Pilot project of joint scientific advice meetings will be evaluated
The pilot project of joint scientific advice meetings arranged by the Dental and Pharmaceutical Benefits Agency (TLV) and the Medical Products Agency (MPA), ended June 30th 2010. The project will be evaluated by the MPA, the TLV and the companies involved during autumn 2010. It is still possible to apply for joint scientific advice until a conclusion has been reached and published regarding the continuation of the project. (Source: MPA RSS news -)
Source: MPA RSS news - - October 4, 2010 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news
